Research analyst, medium-term horizon, biotech, small-cap

Positive Clinical And Commercial Updates From Avita Medical

(Editors' note: This article contains graphic images of burn victims).

Business & Financial Update

Avita Medical Limited (OTCQX:AVMXY) reported total sales for the first half of the year 2014, ended December 31, 2013, of AUD $1.37 million (1 AUD = 0.92 USD). Total sales were up 1.3% from the same period ended December 21, 2012. However, sales of ReCell Spray-On-Skin™ were up 35% in the quarter compared to December 31, 2012 and up 11% for the six-month period ended December 31, 2013. Sales of ReCell grew nicely in the United Kingdom and Australia, up 52% and 29% for the quarter, respectively. Unit sales were up 34% in the UK, 17% in Germany, and 10% in Australia.


Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details